Terra Alpha Investments LLC Invests $1.60 Million in Edwards Lifesciences Co. (NYSE:EW)

Terra Alpha Investments LLC purchased a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 21,580 shares of the medical research company’s stock, valued at approximately $1,598,000. Edwards Lifesciences comprises approximately 1.6% of Terra Alpha Investments LLC’s holdings, making the stock its 24th biggest position.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Abacus Planning Group Inc. increased its stake in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after acquiring an additional 140 shares during the period. Bowman & Co S.C. boosted its holdings in Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after purchasing an additional 148 shares in the last quarter. Moors & Cabot Inc. raised its stake in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock worth $4,041,000 after buying an additional 152 shares in the last quarter. Pegasus Asset Management Inc. lifted its holdings in shares of Edwards Lifesciences by 0.4% in the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after buying an additional 159 shares during the period. Finally, Mount Yale Investment Advisors LLC boosted its stake in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after buying an additional 162 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 2.1 %

Shares of EW opened at $69.37 on Monday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a fifty day moving average of $71.74 and a two-hundred day moving average of $70.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market capitalization of $40.78 billion, a PE ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now directly owns 59,083 shares of the company’s stock, valued at $4,106,859.33. The trade was a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,303 shares of company stock valued at $3,715,776. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.